Memory Pharmaceuticals - Worst Pharma Stocks of 2007
Company: Memory Pharmaceuticals
Starting stock price: $2.69
Ending stock price: $0.56
Percent Change: -79.18%
Details: In March of 2007, Memory's stock took a hit after researchers announced that its lead drug--MEM 1003--failed to achieve any of its endpoints in a mid-stage study for mania in bipolar patients. Results of the same drug as a therapy for Alzheimer's were no better, and the company's stock suffered another major hit in October when MEM 1003 fell short in demonstrating a statistically significant response for improved symptoms after 12 weeks.
More News:
Memory's Alzheimer's drug aces Phase II. Report
Memory's Alzheimer's drug flunks Phase II. Report
Memory shares plunge as lead drug fails trial. Report
More stories about Memory Pharmaceuticals
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
